Navigation Links
Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market
Date:7/28/2011

SEATTLE, July 28, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ and MTA: CTIC) today reported advancements in its efforts to develop its late stage oncology pipeline to market coupled with improved financial results for the second quarter ended June 30, 2011.

"In the second quarter, we seized on the momentum and the feedback provided by the FDA's Office of New Drugs ("OND") in allowing us to resubmit the pixantrone New Drug Application ("NDA") based on the PIX 301 data without requiring the Company to conduct additional clinical trials in advance of potential accelerated approval. Our type A meeting with the FDA's Division of Oncology Drug Products ("DODP") provided guidance on items in the Complete Response Letter and we are on track to provide this information, as well as the information OND requested, in the fourth quarter of 2011," said James A. Bianco, M.D., Chief Executive Officer of the Company. "With a six month review process after resubmission, approval of pixantrone in the United States may occur as early as April 2012.  Similarly, our meeting in April with representatives of the European Medicines Agency ("EMA") and our Marketing Authorization Application ("MAA") co-rapporteurs provided guidance for responding to the Day 120 letter that could allow a recommendation for approval before year end."

"In addition to these significant developments in advancing pixantrone to market, encouraging phase II tosedostat results, which were reported at ASCO, suggest a target population for a phase II/III registration-directed trial, which we expect to get underway in the first half of 2012 following an FDA meeting that we will request later this year. With OPAXIO advancing to its interim survival analysis in the phase III front-line maintenance ovarian cancer study and brostallicin generating excitement in the Mayo Clinic's North Central Cancer Treatment Groups' triple negative breast cancer study, 2012 can be a p
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cell Therapeutics, Inc. Announces Institutional Investors Purchase $30 Million of Preferred Stock and Warrants
2. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
3. Serina Therapeutics, Inc. Closes $9.5 Million Financing Round
4. Cancer Research UK Signs Deal With Centella Therapeutics, Inc. to Launch Clinical Development of Radiotherapy-Enhancing Drug
5. Cell Therapeutics, Inc. Announces Institutional Investors Purchase Approximately $16.0 Million of Preferred Stock and Warrants
6. Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results
7. Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Maintains Target Price of $6.50
8. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
9. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2010 Financial Results on February 16
10. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
11. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 NeuroDerm, ... study in volunteers, and preliminary results from a phase ... presented at the 2013 International Congress of Parkinson,s Disease ... drug formula under development for continuous administration through a ... plasma concentrations. ND0612 has been shown in ...
(Date:6/19/2013)... 19, 2013   Life Technologies Corporation ... agreement granting Suzhou Ribo Life Sciences (Ribo) the ... in China using Life,s ... siRNA molecules in combination with Invivofectamine® Rx to ... diseases with high unmet medical need in the ...
(Date:6/19/2013)... , 19. Juni 2013 ... mit der Entwicklung von SCS microRESIST™, ... in der Beschichtung mit Parylene gelungen ... von biokompatiblem Parylene mit antimikrobiellen Eigenschaften ... schädlicher Mikroorganismen auf beschichteten medizinischen Geräten. ...
Breaking Medicine Technology:NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2
... Group Inc. (Nasdaq: WWIN ; "Winner Medical" or ... and non-woven fabric made from 100% natural PurCotton® products in ... the 2011 Brean Murray, Carret & Co. Beijing China Growth ... at the JW Marriott Hotel located at 83 Jian Guo ...
... SAN DIEGO, June 22, 2011 OncoSec Medical Incorporated ... ElectroOncology therapies to treat solid tumor cancers, announced today ... to OncoSec,s board of directors and will chair its ... For over 20 years, Dr. Maida has ...
Cached Medicine Technology:Winner Medical to Present at Brean Murray, Carret & Co. Beijing China Growth Conference 2Winner Medical to Present at Brean Murray, Carret & Co. Beijing China Growth Conference 3OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors 2OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors 3
(Date:6/19/2013)... CA (PRWEB) June 19, 2013 Alternatives, ... permits some patients to quit using drugs while allowing ... Adi Jaffe, the founders of Alternatives, believe that abstinence-only ... before they enter treatment and that this approach hurts ... million people in the United States need treatment for ...
(Date:6/19/2013)... St. Louis, MO (PRWEB) June 19, 2013 ... solutions organization, partnered with ARAMARK Healthcare Technologies to ... equipment management plan with savings of more than ... repair and maintenance service expenditures. , “Driving economies ... the top medical equipment management challenges facing multi-site ...
(Date:6/19/2013)... a world-leading provider of scientific, technical and medical ... of the National Osteoporosis Guideline Group (NOGG) Update ... postmenopausal women and older men in the journal ... Maturitas , the original guidelines have been ... an additional focus on the management of glucocorticoid-induced ...
(Date:6/19/2013)... Mass. (PRWEB) June 19, 2013 ... security solutions, today announced that Imprivata OneSign ® ... KLAS® 2013 Mid-Term Performance Review: Software & Services report ... KLAS laud Imprivata on the superior performance of its ... support, and they indicate that Imprivata is integral to ...
(Date:6/19/2013)... According to Transparency Market Research “Endoscopy devices Market ... Forecast, 2011 – 2017,” the global endoscopy devices market ... and is expected to reach USD 10.8 billion by ... to 2017. Flexible endoscopes formed the largest category in ... for the year 2011. , Related Report : Medical ...
Breaking Medicine News(10 mins):Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 3Health News:Amerinet Partners with ARAMARK Healthcare Technologies to Help Pacific Medical Centers Save 17 Percent and Better Manage System-Wide Equipment Program 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 3
... NEW YORK, Aug. 7 Duane Reade Holdings, Inc. ... previously announced offers by its wholly-owned subsidiaries, Duane Reade Inc. ... (i) any and all of the Issuers, $210,000,000 outstanding aggregate ... 2010 (the "Floating Rate Notes") (the "FRN Offer") and (ii) ...
... , NEW YORK, Aug. 7 WebMD ... HLTH ) today announced that executives of WebMD are scheduled to ... August 12, 2009 at 1:00 p.m. ET. , , ... to a live audio broadcast of the presentation over the Internet. ...
... The poll results come on the heels of the federal government,s new H1N1 ... A poll conducted by the American Red Cross shows that while a majority ... a third of parents (39%) have received no flu information from their children,s ... http://www.newscom.c o m/cgi-bin/prnh/20090108/RedCrossLOGO ) , , ...
... government to preserve study options , FRIDAY, Aug. 7 (HealthDay ... lines are routinely used by researchers in the United States, says ... known as H1 and H9, accounted for 941 of 1,217 requests, ... stem cell lines housed at the two largest stem cell banks ...
... INDIANAPOLIS Poor communication of the outcomes of medical ... a patient,s hospital discharge is common and can lead ... A new study by researchers from the Regenstrief ... found that hospital discharge summaries are grossly inadequate at ...
... , , WASHINGTON, Aug. 7 "The differences between ... policy experts," say former Chief of Staff to the House Aging Committee ... Americans, lives." , , In an op-ed column in ... Osserman contend, "With no public option, the Senate Finance bill, developed by ...
Cached Medicine News:Health News:Duane Reade Holdings, Inc. Announces Expiration and Results of Tender Offers for Senior Secured Floating Rate Notes and Senior Subordinated Notes and Solicitation of Consents to Related Indentures 2Health News:Duane Reade Holdings, Inc. Announces Expiration and Results of Tender Offers for Senior Secured Floating Rate Notes and Senior Subordinated Notes and Solicitation of Consents to Related Indentures 3Health News:Red Cross Poll Shows Parents Still Lack H1N1 Information From Schools 2Health News:U.S. Stem Cell Research Seems to Focus on Two Lines 2Health News:Fumbled handoffs can lead to medical errors 2Health News:Ex-House Aging Committee Chief of Staff Bob Weiner Warns of Insurance Control Over Health Bill Outcome, Praises House Version, 'Disappointed' by Senate; Weiner and Policy Analyst Jordan Osserman Offer Bill's 'Prognosis' 2
Malaria Pf. Assay Range...
An immunochromatographic test for detection of 4 species of Plasmodium antigen ( P. falciparum , P. vivax , P. malariae , P. ovale ) in whole blood....
192 Test HRP-II Enzyme Immunoassay for the presence of Plasmodium falciparum infection....
Malaria device / strip (3 line, PAN-pLDH, P.f.-HRP2)...
Medicine Products: